{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:37:35Z","timestamp":1792978655436,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493623632"],"award-info":[{"award-number":["493623632"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To evaluate the diagnostic utility of T1\u03c1 mapping for assessing hepatic fibrosis in patients with chronic liver disease (CLD), including steatotic liver disease (SLD).<\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n In this prospective study (September 2024 to May 2025), consecutive patients with CLD underwent liver MRI, including MR-elastography, PDFF, T1, extracellular volume fraction (ECV), and T1\u03c1 mapping. MRE-based liver stiffness was used as the reference to assess the diagnostic performance of the MRI-derived mapping parameters. MR-elastography-based liver stiffness thresholds for significant fibrosis (\u2265\u2009F2) were set at >\u20093.66\u2009kPa for participants without hepatic steatosis (PDFF\u2009\u2264\u20095%), and >\u20093.14\u2009kPa for participants with hepatic steatosis (PDFF\u2009>\u20095%). The\n t<\/jats:italic>\n -test, Spearman\u2019s correlation, and the ROC analysis were applied.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n One hundred twelve CLD participants were included (mean age, 48\u2009\u00b1\u200916 years\n ;<\/jats:italic>\n 53 participants with hepatic steatosis). All assessed quantitative mapping parameters were significantly increased in participants with significant fibrosis than in those without (e.g., T1\u03c1: 110\u2009\u00b1\u200915 vs 92\u2009\u00b1\u20096\u2009ms,\n p<\/jats:italic>\n \u2009<\u20090.001). T1\u03c1 revealed a moderate to strong correlation with MR-elastography-based stiffness, superior to T1 and ECV (entire cohort:\n r<\/jats:italic>\n \u2009=\u20090.75 [T1\u03c1] vs 0.49 [native T1] vs 0.68 [ECV]; participants with hepatic steatosis:\n r<\/jats:italic>\n \u2009=\u20090.67 [T1\u03c1] vs 0.32 [native T1] vs 0.62 [ECV];\n p<\/jats:italic>\n \u2009<\u20090.05 in each case, respectively). T1\u03c1 provided the highest diagnostic performance for diagnosing significant fibrosis (in the entire cohort: AUC 0.90 [T1\u03c1] vs 0.73,\n p<\/jats:italic>\n \u2009<\u20090.001 [native T1], vs 0.81,\n p<\/jats:italic>\n \u2009=\u20090.05 [ECV]; in participants with hepatic steatosis: AUC 0.87 [T1\u03c1] vs 0.67,\n p<\/jats:italic>\n \u2009=\u20090.03 [native T1], vs 0.79,\n p<\/jats:italic>\n \u2009=\u20090.047 [ECV],\n p<\/jats:italic>\n values are given vs T1\u03c1).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Hepatic T1\u03c1 might be a more accurate marker of hepatic fibrosis in CLD, including SLD, compared to hepatic native T1 and ECV mapping.<\/jats:p>\n <\/jats:sec>\n \n Key Points<\/jats:title>\n \n \n Question<\/jats:italic>\n <\/jats:bold>\n Accurate non-invasive assessment of hepatic fibrosis remains challenging, particularly in the presence of steatosis, where MRI biomarkers such as native T1 and ECV fraction are limited<\/jats:italic>\n .\n <\/jats:p>\n \n \n Findings<\/jats:italic>\n <\/jats:bold>\n T1\u03c1 mapping outperformed native T1 and ECV for identifying significant fibrosis and maintained robust accuracy in the presence of hepatic steatosis<\/jats:italic>\n .\n <\/jats:p>\n \n \n Clinical relevance<\/jats:italic>\n <\/jats:bold>\n T1\u03c1 mapping offers a robust, non-invasive MRI biomarker for assessing hepatic fibrosis across the full spectrum of CLD, including SLD, with superior accuracy to native T1 and ECV and reduced influence from hepatic fat infiltration<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Graphical Abstract<\/jats:title>\n <\/jats:sec>","DOI":"10.1007\/s00330-025-12225-5","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T13:14:06Z","timestamp":1766236446000},"page":"3983-3993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical validation of T1\u03c1 mapping for the assessment of hepatic fibrosis in patients with chronic liver disease"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-3965","authenticated-orcid":false,"given":"Narine","family":"Mesropyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Katemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrij","family":"Kravchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yueksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kuetting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus C.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Isaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"12225_CR1","doi-asserted-by":"crossref","unstructured":"EASL, EASD, EASO (2024) EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"12225_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G (2020) Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep 2:100067","journal-title":"JHEP Rep"},{"key":"12225_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Venkatesh SK, Wang Z et al (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13:440\u2013451.e6","journal-title":"Clin Gastroenterol Hepatol"},{"key":"12225_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"J Liang","year":"2023","unstructured":"Liang J, Ampuero J, Niu H et al (2023) An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol 79:592\u2013604","journal-title":"J Hepatol"},{"key":"12225_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13340-9","volume":"12","author":"N Mesropyan","year":"2022","unstructured":"Mesropyan N, Kupczyk PA, Dold L et al (2022) Assessment of liver cirrhosis severity with extracellular volume fraction MRI. Sci Rep 12:9422","journal-title":"Sci Rep"},{"key":"12225_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00330-020-07080-5","volume":"31","author":"N Mesropyan","year":"2021","unstructured":"Mesropyan N, Isaak A, Faron A et al (2021) Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension. Eur Radiol 31:85\u201393","journal-title":"Eur Radiol"},{"key":"12225_CR7","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00261-020-02822-x","volume":"46","author":"N Mesropyan","year":"2021","unstructured":"Mesropyan N, Kupczyk P, Dold L et al (2021) Non-invasive assessment of liver fibrosis in autoimmune hepatitis: diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction. Abdom Radiol (NY) 46:2458\u20132466","journal-title":"Abdom Radiol"},{"key":"12225_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-021-00598-0","volume":"21","author":"N Mesropyan","year":"2021","unstructured":"Mesropyan N, Kupczyk P, Kukuk GM et al (2021) Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis. BMC Med Imaging 21:65","journal-title":"BMC Med Imaging"},{"key":"12225_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1148\/radiol.2018180051","volume":"288","author":"JA Luetkens","year":"2018","unstructured":"Luetkens JA, Klein S, Tr\u00e4ber F et al (2018) Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results. Radiology 288:748\u2013754","journal-title":"Radiology"},{"key":"12225_CR10","doi-asserted-by":"publisher","DOI":"10.1148\/rg.240048","volume":"44","author":"S Hosseini Shabanan","year":"2024","unstructured":"Hosseini Shabanan S, Martins VF, Wolfson T et al (2024) MASLD: what we have learned and where we need to go\u2014a call to action. Radiographics 44:e240048","journal-title":"Radiographics"},{"key":"12225_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347","journal-title":"Hepatology"},{"key":"12225_CR12","doi-asserted-by":"publisher","unstructured":"Mesropyan N, Huaroc Moquillaza E, Chang J et al (2025) Dixon-based water T1 mapping for fat-corrected assessment of hepatic fibrosis in chronic liver disease. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000001212","DOI":"10.1097\/RLI.0000000000001212"},{"key":"12225_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/liv.13284","volume":"37","author":"M Pavlides","year":"2017","unstructured":"Pavlides M, Banerjee R, Tunnicliffe EM et al (2017) Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int 37:1065\u20131073","journal-title":"Liver Int"},{"key":"12225_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/RLI.0000000000001084","volume":"59","author":"JB Klaus","year":"2024","unstructured":"Klaus JB, Goerke U, Klarh\u00f6fer M et al (2024) MRI dixon fat-corrected look-locker T1 mapping for quantification of liver fibrosis and inflammation\u2014a comparison with the non-fat-corrected shortened modified look-locker inversion recovery technique. Invest Radiol 59:754\u2013760","journal-title":"Invest Radiol"},{"key":"12225_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/RLI.0000000000001193","volume":"60","author":"N Mesropyan","year":"2025","unstructured":"Mesropyan N, Schneider F, Lutz PC et al (2025) Multiparametric MRI including T1\u03c1 mapping for hepatic fibrosis assessment in preclinical models of steatotic liver disease. Invest Radiol 60:679\u2013687. https:\/\/doi.org\/10.1097\/RLI.0000000000001193","journal-title":"Invest Radiol"},{"key":"12225_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837\u2013845","journal-title":"Biometrics"},{"key":"12225_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44377-y","volume":"9","author":"VC Obmann","year":"2019","unstructured":"Obmann VC, Mertineit N, Marx C et al (2019) Liver MR relaxometry at 3T\u2014segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness. Sci Rep 9:8106","journal-title":"Sci Rep"},{"key":"12225_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/jmri.24677","volume":"41","author":"L Wang","year":"2015","unstructured":"Wang L, Regatte RR (2015) T\u2081\u03c1 MRI of human musculoskeletal system. J Magn Reson Imaging 41:586\u2013600","journal-title":"J Magn Reson Imaging"},{"key":"12225_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12968-023-00940-1","volume":"25","author":"A Bustin","year":"2023","unstructured":"Bustin A, Witschey WRT, van Heeswijk RB, Cochet H, Stuber M (2023) Magnetic resonance myocardial T1\u03c1 mapping: technical overview, challenges, emerging developments, and clinical applications. J Cardiovasc Magn Reson 25:34","journal-title":"J Cardiovasc Magn Reson"},{"key":"12225_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.mri.2015.10.017","volume":"34","author":"J Jiang","year":"2016","unstructured":"Jiang J, Huang B, Bin G, Chen S, Feng F, Zou L (2016) An experimental study on the assessment of rabbit hepatic fibrosis by using magnetic resonance T1\u03c1 imaging. Magn Reson Imaging 34:308\u2013311","journal-title":"Magn Reson Imaging"},{"key":"12225_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1148\/radiol.11101638","volume":"259","author":"Y-XJ Wang","year":"2011","unstructured":"Wang Y-XJ, Yuan J, Chu ESH et al (2011) T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. Radiology 259:712\u2013719","journal-title":"Radiology"},{"key":"12225_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12876-020-1161-3","volume":"20","author":"S Xie","year":"2020","unstructured":"Xie S, Qi H, Li Q et al (2020) Liver injury monitoring, fibrosis staging and inflammation grading using T1rho magnetic resonance imaging: an experimental study in rats with carbon tetrachloride intoxication. BMC Gastroenterol 20:14","journal-title":"BMC Gastroenterol"},{"key":"12225_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00330-012-2419-0","volume":"22","author":"F Zhao","year":"2012","unstructured":"Zhao F, Wang Y-XJ, Yuan J et al (2012) MR T1\u03c1 as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication. Eur Radiol 22:1709\u20131716","journal-title":"Eur Radiol"},{"key":"12225_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3348\/kjr.2017.18.6.898","volume":"18","author":"S Xie","year":"2017","unstructured":"Xie S, Li Q, Cheng Y et al (2017) Impact of liver fibrosis and fatty liver on T1rho measurements: a prospective study. Korean J Radiol 18:898\u2013905","journal-title":"Korean J Radiol"},{"key":"12225_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1148\/radiol.13130342","volume":"271","author":"T Allkemper","year":"2014","unstructured":"Allkemper T, Sagmeister F, Cicinnati V et al (2014) Evaluation of fibrotic liver disease with whole-liver T1\u03c1 MR imaging: a feasibility study at 1.5 T. Radiology 271:408\u2013415","journal-title":"Radiology"},{"key":"12225_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jmri.24739","volume":"42","author":"Y Takayama","year":"2015","unstructured":"Takayama Y, Nishie A, Asayama Y et al (2015) T1 \u03c1 relaxation of the liver: a potential biomarker of liver function. J Magn Reson Imaging 42:188\u2013195","journal-title":"J Magn Reson Imaging"},{"key":"12225_CR27","doi-asserted-by":"crossref","unstructured":"Kemp J, Manhard MK, Tkach JA et al (2024) Influence of fat on hepatic T2 relaxation time estimation: a preliminary investigation. Abdom Radiol (NY) 50:1606\u20131614","DOI":"10.1007\/s00261-024-04623-y"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12225-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12225-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12225-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:23:32Z","timestamp":1776338612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12225-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["12225"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12225-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Narine Mesropyan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors affiliated with Philips Healthcare (C.K. and O.M.W.), who supported the development of the T1\u03c1 mapping sequence, had no role in the study design, data acquisition, analysis, or interpretation of the results. The remaining authors declare no conflicts of interest related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Only if the study is on human subjects: written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained (no. 155\/23-EP).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A subset of patients (\n n\n \u2009=\u200927\/112) included in the present study was also part of a recently published cohort (\n \n ). This overlap is due to partially joint recruitment during a partially overlapping study period. However, this had no impact on the current study results, as the previous study focused on the evaluation of a newly developed Dixon-based water T1 mapping sequence for fat corrected assessment of hepatic fibrosis. The present study represents the clinical translation of earlier preclinical work in animal models of SLD (\n \n ), which investigated the diagnostic value of T1\u03c1 mapping for assessing liver fibrosis in CLD, including SLD.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}